JADPRO Live 2017 Educational Activities

These educational activities are based on presentations from JADPRO Live at APSHO 2017. Access the full-length video presentation, the slide deck, transcript, and the entire lecture as a podcast. Click on any of the video presentations below to get started!

All  |  AML  |  AML  |  BRCA  |  Immunotherapy  |  Immunotherapy  |  Immunotherapy  |  Immunotherapy  |  PARP  |  CML  |  MDS  |  MPN  |  Colon Cancer  |  Colorectal Cancer  |  Lynch Syndrome  |  mCRC  |  MSI-H  |  Rectal Cancer  |  CAR T-Cell Therapy  |  irAEs  |  irAEs  |  Side Effect Management  |  ALK Positive NSCLC  |  EGFR Resistance  |  Lymphomas and Leukemias  |  Bladder Cancer  |  Urothelial Carcinoma  |  GIST  |  Leiomyosarcoma  |  Soft Tissue Sarcomas  |  Surgery  |  Drug Development  |  MRD  |  Multiple Myeloma  |  Oral Therapies  |  Risk Stratification  |  Adjuvant Treatment  |  Breast Cancer  |  Diarrhea  |  HER2 Positive Breast Cancer
A Deeper Dive into Advanced and Future Directions in Treating Patients with Acute Myeloid Leukemia

Supported by unrestricted educational grants from Astellas Pharma Global Development, Inc. and Jazz Pharmaceuticals.

A Deeper Dive into Advanced and Future Directions in Treating Patients with Acute Myeloid Leukemia

Hear from expert advanced practitioners about the updated WHO classification criteria and today’s leading-edge treatments for AML. Also learn about the molecular mutations commonly associated with this disease and how to identify patients who are genetically predisposed.

Posted: January 22, 2018 / Expires: January 22, 2019

This certified activity has expired but you may watch the video without claiming credit.

Watch Video Without Claiming Credit

New Drug Updates in Solid Tumors: PARP Inhibitors in Ovarian Cancer, Immunotherapeutics, and Other Agents

This activity is supported by independent educational grants from AstraZeneca, Merck Sharp & Dohme Corp, Novartis Pharmaceuticals Corporation, Puma Biotechnology, Takeda Oncology, and TESARO, Inc.

New Drug Updates in Solid Tumors: PARP Inhibitors in Ovarian Cancer, Immunotherapeutics, and Other Agents

Get updated on the latest drug treatments for solid tumors and the clinical trial data behind their FDA approvals. And importantly, learn how to spot the common adverse side effects from these newly approved treatments and how to help patients manage them.

Posted: January 22, 2017 / Expires: January 22, 2018

This certified activity has expired but you may watch the video without claiming credit.

Watch Video Without Claiming Credit

Managing the Continuum of Myeloid Malignancies

This activity is supported by independent educational grants from Astellas Pharma Global Development, Inc., Celgene Corporation, and Jazz Pharmaceuticals.

Managing the Continuum of Myeloid Malignancies (CML, MPN, MDS, and AML)

Take a deep dive into the updated WHO criteria for diagnosing myeloid malignancies, the mechanisms of action of new novel therapies, and the growing role of molecular mutations, while also learning how to take a collaborative, multidisciplinary approach to classifying these diseases. Advanced practitioners are key to managing the evolving continuum of myeloid malignancies and creating a multidisciplinary team approach to managing patients with complex myeloid malignancies.

Posted: January 22, 2018 / Expires: January 22, 2019

This certified activity has expired but you may watch the video without claiming credit.

Watch Video Without Claiming Credit

Hereditary Aspects of Colorectal Cancer

This activity is supported by an independent educational grant from Merck Sharp & Dohme Corp.

Hereditary Aspects of Colorectal Cancer

Learn about Lynch syndrome and other hereditary colorectal cancer syndromes, in addition to which patients are at risk, how to screen for these syndromes, and the relationship between biomarkers and targeted therapies for colorectal cancer. With 95% of Americans with Lynch syndrome unaware of their condition, it is vital that advanced practitioners in oncology be well-versed in the hereditary aspects of colorectal cancer to ensure patients are diagnosed effectively and receive the appropriate treatment.

Posted: January 22, 2018 / Expires: January 22, 2019

This certified activity has expired but you may watch the video without claiming credit.

Watch Video Without Claiming Credit

New Drug Updates in Hematologic Malignancies

This activity is supported by independent educational grants from Merck Sharp & Dohme Corp, Novartis Pharmaceuticals Corporation, Puma Biotechnology, Takeda Oncology.

New Drug Updates in Hematologic Malignancies: CAR T Cells, Targeted Therapeutics, and Other Agents

Get an update on the fast-changing world of therapies for hematologic malignancies. With the constantly growing list of new drugs and indications, as well as the introduction of cutting-edge CAR T-cell therapy for the treatment of hematologic malignancies, it’s important that advanced practitioners stay up to date on the latest advances to be able to adequately diagnose, treat, and help patients navigate potential side effects.

Posted: January 22, 2018 / Expires: January 22, 2019

This certified activity has expired but you may watch the video without claiming credit.

Watch Video Without Claiming Credit

Managing Side Effects of Cancer Patients Treated With Immunotherapy

This activity is supported by independent educational grants from AstraZeneca, Bristol-Myers Squibb, and Merck Sharp & Dohme Corp.

Managing Side Effects of Cancer Patients Treated With Immunotherapy

Learn how to identify, assess, and manage the possible side effects from cancer immunotherapy, as well as how to educate patients on what to expect from treatment. With the constantly growing list of FDA-approved immunotherapies for cancer, it is vital that advanced practitioners in oncology remain up-to-date on this cutting-edge treatment area, including the questions that research has yet to answer.

Posted: January 22, 2018 / Expires: January 22, 2019

This certified activity has expired but you may watch the video without claiming credit.

Watch Video Without Claiming Credit

Advances in the Use of Targeted Therapies in the Management of Non–Small Cell Lung Cancer

This activity is supported by independent educational grants from AstraZeneca, Pfizer, and Takeda Oncology.

Advances in the Use of Targeted Therapies in the Management of Non–Small Cell Lung Cancer

Learn about the recent updates in the world of genetic testing and targeted therapies for non–small cell lung cancer. It’s vital that advanced practitioners in oncology have the latest knowledge on EGFR, ALK, and BRAF inhibitors, as well as acquired resistance mutations, to help patients from diagnosis through treatment.

Posted: January 22, 2018 / Expires: January 22, 2019

This certified activity has expired but you may watch the video without claiming credit.

Watch Video Without Claiming Credit

Applying Genomics to Rare Lymphomas and Leukemias

This activity is supported by an independent educational grant from Merck Sharp & Dohme Corp.

Applying Genomics to Rare Lymphomas and Leukemias (Hodgkin Lymphoma and Chronic Lymphocytic Leukemia)

Review how genomics are being used to treat rare hematologic malignancies such as Hodgkin lymphoma, chronic lymphocytic leukemia, and mantle cell lymphoma. And learn how, as an advanced practitioner, to evaluate toxicities from these cutting-edge therapies and how to help patients navigate the potential side effects.

Posted: January 22, 2018 / Expires: January 22, 2019

This certified activity has expired but you may watch the video without claiming credit.

Watch Video Without Claiming Credit

Advances in the Management of Patients with Urothelial Carcinomas of the Bladder

This activity is supported by an independent educational grant from Merck Sharp & Dohme Corp.

Advances in the Management of Patients with Urothelial Carcinomas of the Bladder

Get an update on the state of chemotherapy and immunotherapy for the treatment of urothelial carcinomas of the bladder. Learn how these therapies combat the various types of urothelial carcinomas and how to identify their most common side effects, including immune-related adverse effects from immunotherapy.

Posted: January 22, 2018 / Expires: January 22, 2019

This certified activity has expired but you may watch the video without claiming credit.

Watch Video Without Claiming Credit

Optimizing Outcomes for Patients With Soft-Tissue Sarcomas

This activity is supported by an independent educational grant from Lilly USA, LLC.

Optimizing Outcomes for Patients With Soft-Tissue Sarcomas Through the Multidisciplinary Medical Oncology/Radiation/Surgical Team Approach

Discover how to cultivate and personalize a multidisciplinary approach—involving the medical oncology, radiation, and surgical teams—to treating patients with soft tissue sarcoma in your own institution. In addition, get an update on the staging criteria and current state of systemic, surgical, and radiation therapy options for this disease.

Posted: January 22, 2018 / Expires: January 22, 2019

This certified activity has expired but you may watch the video without claiming credit.

Watch Video Without Claiming Credit

An Address From Dr. Richard Pazdur: How the Changing Landscape of Oncology Drug Development and Approval Will Affect Advanced Practice

Get an inside perspective on how the FDA updates its drug approval processes to reflect the changing oncology treatment environment and to incorporate the voice of the patient. With increasing numbers of oncology drug approvals and the ever-important area of molecularly targeted therapy, it is critical that advanced practitioners embrace and support this change.

Posted: January 22, 2018 / Expires: January 22, 2019

This certified activity has expired but you may watch the video without claiming credit.

Watch Video Without Claiming Credit

Risk Stratification in Multiple Myeloma

This activity is supported by unrestricted educational grants from Celgene Corporation and Takeda Oncology.

Risk Stratification in Multiple Myeloma: Putting the Pieces Together

While the past few years have shown an unprecedented increase in the number of agents available to treat patients with multiple myeloma, many advanced practitioners struggle with optimal agent choice, timing, and sequencing, especially related to the use of these newer agents in combination regimens. Learn about these aspects of treatment, as well as testing and diagnosis, risk stratification, emerging toxicities, and supporting patients on oral therapies.

Posted: January 22, 2018 / Expires: January 22, 2019

This certified activity has expired but you may watch the video without claiming credit.

Watch Video Without Claiming Credit

Advances in Extended Adjuvant HER2-Positive Early Breast Cancer

Supported by an educational grant from Puma Biotechnology.

Advances in Extended Adjuvant HER2-Positive Early Breast Cancer

Examine the mechanisms of action of extended adjuvant therapies for HER2-positive early breast cancer, in addition to strategies for combating patients’ side effects and the latest guidelines on HER2 testing. Advanced practitioners can also learn about their critical role in properly selecting patients for treatment, educating them about their treatment options, and managing treatment adherence.

Posted: January 22, 2018 / Expires: January 22, 2019

This certified activity has expired but you may watch the video without claiming credit.

Watch Video Without Claiming Credit


Copyright © 2010-2019 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.